These results lead us to an important hypothesis that, while normal cancer cells induce immune cells in systemic circulation reflecting the anti-cancer inflammation, the NRF2-activated cancers acquire a unique ability to grow without inducing both immune cells in systemic circulation and anti-tumor inflammation. The gene discussed is NFE2L2; the disease is cancer.